A team of inventive scientists, tech entrepreneurs and pioneering practitioners working in tandem to catalyze successful health innovation.
Dr. Michael Shleifer
Co-Founder, Managing
Partner
Ivan Jarry
Co-Founder
Al Hummel
Senior Partner
Thomas Fratacci
Chief Financial Officer
Daniel Martinez
VP Clinical Trials Financing
Mark Hasleton
VP Clinical Trials Financing
Tassos Konstantinou
TrialCap, Managing Director
Elizabeth Wang
TrialCap, Director, Credit Structuring
Chong Wee Khoo
Financial Controller
Chang Chu Chuen
Investment Analyst
Maddy Hoang
Investment Analyst
Janice Wong
Accountant
Hartini Ismail
HR Executive
Shamini Chandran
Administrative Assistant
Jame Tan
IT Manager
Joline Lim
Senior Graphic Designer
SGI At A Glance
Founded in 2008, SPRIM Global Investments (SGI) is a privately held investment firm specializing in clinical-stage life sciences and pharma services. SGI’s innovative investment model provides agile and high-impact funding to high-potential biotech companies worldwide, supporting the advancement of clinical trials and accelerating the development of life-changing treatments.
We work with dynamic companies proposing innovative treatments and solutions and help them to accelerate their growth and achievements. These companies can, in turn, leverage the SPRIM network, enabling them to fast-track their development. Our portfolio companies have full access to SPRIM’s fellow venture company experts across the globe.
Areas Of Focus
SPRIM Global Investments invests principally in companies that provide R&D capabilities to bring life science, biotech and medtech innovations to patients around the world. Our portfolio of R&D Service/CRO and digital technology companies are addressing many of the pain points across the different clinical stages of drug and device development. Additionally, SGI leverages its unique vantage point in clinical stages to invest in Biotech and in Medtech.
We Build Companies For The Future Of Health.
SPRIM believes in maximizing the potential of innovative digital health and life science innovations by providing scientific, clinical and entrepreneurial expertise to foster bold, new, innovative solutions to the world’s biggest health problems.
Our portfolio companies leverage the capabilities and network of SGI investments in R&D Services, Healthcare IT and digital solutions across 17 offices, strategically placed throughout Asia-Pacific, Europe and the Americas.
Headquarters
New York
545 West 25th Street,
20th Floor New York,
NY, USA 10001
Singapore
79 Science Park Drive
Level 06 Unit 01/08
CINTECH IV, Science Park 1
Singapore 118264
We invest to bring better solutions for companies to develop and commercialize their innovations in life science.
The Criteria
R&D Services/CRO and Digital Health/HCIT
From early stage to growth stage, we look for innovative services and software solutions to improve the conduct and outcomes of clinical trials, regulatory processes and commercialization of drugs and medical technologies.
Biotech
We invest in preclinical as well as clinical stage companies, primarily in neurology, oncology and fibrosis.
Medtech
We invest in medtech and digital therapeutics after tne PoC stage.
